{
  "judge_id": "journey",
  "lens": "journey",
  "evidence_viewed": [
    "evidence/asset-001.jpg",
    "evidence/asset-002.jpg",
    "evidence/asset-003.jpg",
    "evidence/asset-004.jpg",
    "evidence/asset-005.jpg",
    "evidence/asset-006.jpg",
    "evidence/asset-007.jpg",
    "evidence/asset-008.jpg",
    "evidence/asset-009.jpg",
    "evidence/asset-010.jpg",
    "evidence/asset-011.jpg",
    "evidence/asset-012.jpg",
    "evidence/asset-013.jpg",
    "evidence/asset-014.jpg",
    "evidence/asset-015.jpg",
    "evidence/asset-016.jpg",
    "evidence/asset-017.jpg",
    "evidence/asset-018.jpg",
    "evidence/asset-019.jpg",
    "evidence/asset-020.jpg",
    "evidence/asset-021.jpg",
    "evidence/asset-022.jpg",
    "evidence/asset-023.jpg",
    "evidence/asset-024.jpg",
    "evidence/asset-025.jpg",
    "evidence/asset-026.jpg",
    "evidence/asset-027.jpg",
    "evidence/asset-028.jpg",
    "evidence/asset-029.jpg",
    "evidence/asset-030.jpg",
    "evidence/asset-031.jpg",
    "evidence/asset-032.jpg",
    "evidence/asset-033.jpg",
    "evidence/asset-034.jpg",
    "evidence/asset-035.jpg",
    "evidence/asset-036.jpg",
    "evidence/asset-037.jpg",
    "evidence/asset-038.jpg",
    "evidence/asset-039.jpg",
    "evidence/asset-040.jpg",
    "evidence/asset-041.jpg",
    "evidence/asset-042.jpg",
    "evidence/asset-043.jpg",
    "evidence/asset-044.jpg",
    "evidence/asset-045.jpg"
  ],
  "page": {
    "scores": {
      "visual_craft": 8.6,
      "brand_distinctiveness": 8.2,
      "journey_flow": 8.0,
      "trust_proof": 8.1,
      "offer_clarity": 8.3,
      "mobile_usability": 7.7
    },
    "dimension_evidence": {
      "visual_craft": "Strengths: Controlled forest-green/cream contrast, expressive sans/italic typography, polished product photography and generous desktop composition create a cohesive presentation (asset-015.jpg, asset-017.jpg, asset-020.jpg). Gallery photography maintains the same visual language across subjects and sizes (asset-036.jpg–asset-043.jpg). Flaws: The floating CTA visibly overlaps headings and testimonial content (asset-018.jpg, asset-019.jpg, asset-021.jpg); the square final offer panel departs from the rounded primary purchase card (asset-016.jpg, asset-024.jpg). Limitation: Screenshots cannot establish animation quality or rendering stability.",
      "brand_distinctiveness": "Strengths: Prismatic packaging, dark stone, curved glass and recurring italic emphasis provide recognizable visual anchors (asset-015.jpg, asset-017.jpg, asset-020.jpg, asset-041.jpg). Plain-language ingredient and label sections reinforce a consistent transparency theme (asset-004.jpg, asset-018.jpg). Flaws: Later review cards and FAQ styling become more conventional, and the packaging's distinctive iridescence has little expression outside photography (asset-022.jpg, asset-023.jpg). Limitation: No competitive comparison establishes category-level uniqueness.",
      "journey_flow": "Strengths: The sequence moves coherently from problem and offer through ingredients, label/testing, customer stories, daily use, questions and a final purchase opportunity (asset-015.jpg–asset-024.jpg). Formula links, batch-report entry points and a repeated offer support different decision paths (asset-002.jpg, asset-003.jpg, asset-018.jpg). Flaws: Mobile separates the opening proposition from the purchase controls with testimonial and gallery content; the selected subscription card then requires further scrolling to reach its primary button (asset-001.jpg, asset-029.jpg, asset-003.jpg). The sticky CTA also interrupts supporting content (asset-007.jpg, asset-009.jpg). Limitation: Screenshots show resulting states, not actual anchor behavior, checkout completion or interaction timing.",
      "trust_proof": "Strengths: The full label, manufacturing geography, named laboratory, batch identifier, dated report, original-PDF link and batch lookup make proof unusually concrete (asset-006.jpg, asset-018.jpg, asset-026.jpg, asset-034.jpg). The expanded explanation distinguishes laboratory measurement from formulation records, a valuable qualification to preserve (asset-035.jpg). Named video accounts, original-source links, purchaser badges and accessible return language add reassurance (asset-008.jpg, asset-022.jpg, asset-032.jpg). Flaws: The prominent 2,600 five-star-review claim lacks visible source or rating-distribution context, while the shown review collection is uniformly positive (asset-001.jpg, asset-022.jpg, asset-031.jpg). Limitation: Review authenticity, report contents, laboratory claims and linked policies were not independently verified.",
      "offer_clarity": "Strengths: Both purchase states clearly distinguish the free subscription introduction with $9.99 shipping and $50.99 every two months from the $59.99 one-time purchase; cancellation flexibility and no-recurring-order language are explicit (asset-002.jpg, asset-003.jpg, asset-016.jpg). The final offer repeats renewal terms beside its CTA (asset-013.jpg, asset-024.jpg). Flaws: The persistent 'FREE first bottle' bar omits shipping and subscription qualifications when the detailed offer is offscreen (asset-008.jpg, asset-012.jpg, asset-020.jpg). One-time shipping remains unspecified in the visible purchase panel (asset-002.jpg). Limitation: Checkout totals and subsequent renewal-shipping treatment are not shown.",
      "mobile_usability": "Strengths: The layout remains readable at 360px, purchase options have large selectable areas, carousel previews signal additional content, and the report modal stacks its form appropriately (asset-025.jpg, asset-003.jpg, asset-008.jpg, asset-026.jpg). The supplementary gallery states fit their narrow containers without obvious text clipping (asset-036.jpg–asset-040.jpg). Flaws: The bottom purchase bar repeatedly covers label details, routine instructions and carousel controls (asset-006.jpg, asset-007.jpg, asset-009.jpg). Gallery captions are very small, and the subscription purchase card is taller than one supplied mobile viewport (asset-029.jpg, asset-003.jpg, asset-036.jpg). Limitation: Touch behavior, keyboard handling, screen-reader support and modal focus management cannot be established visually."
    },
    "blockers": [
      "The floating purchase bar visibly obscures decision-support content, including the supplement label, routine instructions and testimonial navigation (asset-006.jpg, asset-007.jpg, asset-009.jpg), with desktop overlap as well (asset-021.jpg). Highest-impact fix: reserve a dedicated bottom region for the bar and keep scrollable content and controls outside its footprint.",
      "The persistent offer becomes materially less complete away from the purchase panels: 'FREE first bottle' appears without the $9.99 shipping charge or subscription requirement (asset-008.jpg, asset-012.jpg, asset-020.jpg), although those terms are clearly disclosed in asset-003.jpg. Highest-impact fix: qualify the sticky offer with shipping and subscription language while retaining the complete renewal disclosure at purchase.",
      "The mobile purchase route takes too much vertical space: the opening offer precedes a testimonial and gallery, and the subscription panel places multiple benefit columns above the price and purchase button (asset-001.jpg, asset-029.jpg, asset-003.jpg). Highest-impact fix: put the selected offer's price, renewal terms and primary CTA immediately beneath the purchase options, moving the benefit summary below them."
    ],
    "evidence_limitations": [
      "Assessment uses the supplied screenshots; no live interaction or checkout was tested.",
      "Measured performance is unknown. No loading, responsiveness or layout-shift measurements were supplied.",
      "FAQ answers, most report accordion contents, batch-search results, original PDFs, policy destinations and video playback are not shown.",
      "Alternate-state screenshots establish visible presentation, not whether selections synchronize across purchase panels or persist during navigation.",
      "Accessibility beyond visible layout and controls is unverified; screenshot overlap does not establish that underlying content is permanently inaccessible.",
      "No conversion lift, commercial outcome, clinical effectiveness or independent proof authenticity can be inferred from this evidence."
    ]
  }
}